LONDON, GREATER LONDON, UNITED KINGDOM, March 13, 2025 /EINPresswire / -- How Has the Unituxin Market Evolved, and What Is Its Projected Size for 2025? .The Unituxin market has experienced notable ...
Hosted on MSN27d
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatIt also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. Revenues came in at $735.9 million, beating the Zacks Consensus Estimate of $725.3 million. Revenues rose 20% ...
Double-digit growth in key products, including Tyvaso, Remodulin, Orenitram, and Unituxin, contributed to the financial success. United Therapeutics Corporation (NASDAQ:UTHR)’s Tyvaso revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback